DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
DexCom Price Performance
DXCM opened at $70.26 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market capitalization of $27.46 billion, a P/E ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.28. The company's 50-day simple moving average is $84.53 and its two-hundred day simple moving average is $76.98. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.
DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.
Hedge Funds Weigh In On DexCom
Several institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. bought a new stake in DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Finally, Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares during the period. Institutional investors own 97.75% of the company's stock.
Analyst Upgrades and Downgrades
DXCM has been the topic of several research reports. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and increased their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $99.82.
Check Out Our Latest Research Report on DexCom
DexCom Company Profile
(
Get Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
